Skip to Main Content
Contribute Try STAT+ Today

Hello, everyone, and nice to see you again. We are happy to report that we have returned in one piece from an extended round of schmoozing and kibbitzing in the swamp, where we encountered a delightful mix of old and new contacts. We thank them for their time. Now, though, we must return to the usual routine, which of course, includes a few cups of stimulation — our choice today is milk chocolate caramel, seriously. Meanwhile, here are your tidbits. Have a smashing day and do keep us in mind when you run across secret dossiers …

Astellas Pharma is the latest drug maker to reveal it is a subject of a U.S. probe into pharmaceutical industry support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs, Reuters reports. In a lawsuit filed against its insurers, the drug maker disclosed that the U.S. Justice Department was conducting a joint criminal and civil investigation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.